No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 4.2x · 10Y median 3.8x · 70th percentile · as of Dec 31, 2025
Annual revenue · last 11 fiscal years
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Roche Holding AG (RHHBY) stock was $56.39 as of Aug 27, 2026, 4:00 PM EDT, down 0.88% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +42.1% · 3-year avg +19.4%/yr · 5-year avg +5.8%/yr
Roche Holding AG functions as a major global healthcare enterprise, primarily concentrating its efforts within the pharmaceutical and diagnostic sectors. The company boasts an extensive international presence, with key operations located in countries such as Switzerland, Germany, the United States, Austria, the Netherlands, the United Kingdom, France, and Belgium.
Drug Manufacturers - General · Basel, BS
Next Earnings Date
Feb 4, 2027
160 days away
EPS Estimate
1.49
Revenue Est.
$39.79B
Last Quarter Results
EPS
$1.66
vs Estimate
$1.58
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1RHHBY | $359.46B | $56.39 | -0.88% | +42.08% | +5.84% | +9.59% | N/A |
| 2UNH | $358.76B | $395.05 | -1.49% | +33.52% | +0.60% | +13.05% | vs RHHBY |
| 3MRK | $369.34B | $149.54 | -2.33% | +86.28% | +18.50% | +13.26% | vs RHHBY |
| 4ABBV | $455.87B | $258.02 | -1.86% | +30.12% | +21.30% | +19.90% | vs RHHBY |
| 5AZN | $255.15B | $164.52 | -1.05% | +4.41% | +9.31% | +12.70% | vs RHHBY |
| 6AMGN | $235.85B | $436.99 | -0.76% | +56.31% | +18.37% | +13.18% | vs RHHBY |
TTM
4.53
$38.52B
vs Estimate
$38.14B
Consensus Rating
Based on 7 analysts
Average Price Target
$59.66
+5.8% upside
Low
$53.00
Current
$56.39
High
$67.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Dec 2026 | CHF 0.00 | CHF 0.00 | CHF 0.00 | 0 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | CHF 2.11 | CHF 2.47 | CHF 2.58 | 5 |
| FY 2027 | CHF 2.34 | CHF 2.67 | CHF 2.79 | 5 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Dec 2026 | CHF 12.95B | CHF 13.00B | CHF 13.06B | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | CHF 59.62B | CHF 61.51B | CHF 63.44B | 9 |
| FY 2027 | CHF 61.03B | CHF 64.21B | CHF 66.43B | 10 |
Source: FMP Analyst Consensus Estimates. Forward P/E uses the next-fiscal-year consensus EPS estimate (the same value shown in the Key Metrics strip).
